ASCO GU 2022

Neoadjuvant therapy in UTUC: Good options for selected patients

ADC in bladder cancer: defining the future!

Role of PARPi in urothelial cancer

PARPi in urothelial cancer: DFS advantage for the DDR+, OS data pending.

ADCs will be step-changing in urothelial cancers

Patient selection for bladder preservation

HER2 ERBB2 – entering precision oncology

ADC shape the therapy landscape in urothelial cancer

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Follow-up data confirm OS benefit across subgroups

IO escalation results in improved response in met. TCC.

Ongoing immunotherapy innovation for mCRPC

Exciting data supports trimodality therapy

Mature data confirm efficacy of maintenance avelumab as standard of care

Not practice changing, but hypothesis generating.

Do we need testing? Which biomarkers are of relevance?

Enza beyond progression? Practice changing or not?

Triplet vs. doublet: Which patients should we consider?

Theranostics – Presence and future: Vision, PSMAfore, PSMAAddition, TheraP

The future of genetic testing. Somatic vs. germline? International perspectives

Is biomarker development taking a back seat in prostate cancer?

The importance of conducting HCRA

New therapies and molecular targets in prostate cancer

PRESIDE indicates benefit of continuation ENZA + ADT

PSA response correlates with OS and benefits in QoL

Should we use arbiraterone and niraparib as 1st line treatment of mCRPC with BRCA1/2 mutation?

How to improve PSMA based radioligand therapy

Addition of darolutamide improves OS in met. hormone-sensitive PC

Is the dual hormone-backbone the future?

Exciting new compound for mCRPC

Should we use arbiraterone and olaparib as 1st line treatment of mCRPC?

PSMA and FDG PET as biomarkers for response to LuPSMA

HRR testing: MAGNITUDE vs. PROpel

Where do PROpel and Magnitude agree?

Triplet-therapy as a novel treatment option

The need for biomarker panels in biopsy decision making

Subgroup analyses confirm the importance of oral daily GnRH Antagonist - relugolix

DARO in triplet therapy for CRPC

PROpel & Magnitude: who wins the race?

Is docetaxel still needed for hormone sensitive mCRPC?

Neoadjuvant IO+TKI Treatment: We need more data on efficient IO/TKI combinations

Treatment options following adjuvant PD1 Therapy: Uncertainty of choices!

Thoughts on first line treatment options following ASCO GU 2022

Adjuvant PD1 Therapy confirms significant benefit for high-risk patients. An individual risk benefit assessment is required!

Consistent OS benefit confirmed. Consider overtreatment vs. undertreatment!

Microbioma modification and checkpoint inhibition

Adjuvant Pembroluzimab update in kidney cancer

Nivo montoherapy followed by Nivi-Ipi resuce

CheckMate final OS Follow Up and health related QoL

Neoadjuvant avelumab/axitinib - NeoAvAx

Update in neoadjuvant therapy for kidney cancer

Frontline treatment of metastatic kidney cancer

Update in adjuvant therapy for kidney cancer

Data gap in 2nd line RCC: what’s new?